Mouse models of Huntington's disease

Author： Menalled L.B.   Chesselet M.-F.  

Publisher： Elsevier

ISSN： 0165-6147

Source： Trends in Pharmacological Sciences, Vol.23, Iss.1, 2002-01, pp. : 32-39

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Human embryonic stem cell models of Huntington disease

By Niclis JC   Trounson AO   Dottori M   Ellisdon AM   Bottomley SP   Verlinsky Y   Cram DS  

Reproductive BioMedicine Online, Vol. 19, Iss. 1, 2009-07 ,pp. : 106-113

Reproductive Healthcare Ltd

Access to resources Recommend Favorite

Transgenic Mouse Models of Parkinson's Disease and Huntington's Disease

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 9, Iss. 4, 2010-08 ,pp. : 455-470

Bentham Science Publishers

Access to resources Recommend Favorite

Gabapentin-lactam, but not gabapentin, reduces protein aggregates and improves motor performance in a transgenic mouse model of Huntington’s disease

By Zucker Birgit   Ludin Dagmar   Gerds Thomas   Lücking Carl   Landwehrmeyer G.   Feuerstein Thomas  

Naunyn-Schmiedeberg's Archives of Pharmacology, Vol. 370, Iss. 2, 2004-08 ,pp. : 131-139

Springer Publishing Company

Access to resources Recommend Favorite

The Endocannabinoid System and Huntington's Disease

By  

Current Drug Targets-CNS & Neurological Disorders, Vol. 2, Iss. 5, 2003-10 ,pp. : 335-347

Bentham Science Publishers

Access to resources Recommend Favorite

Neuroprotection in Huntington;s Disease

By  

Letters in Drug Design & Discovery, Vol. 2, Iss. 2, 2005-03 ,pp. : 143-147

Bentham Science Publishers

Access to resources Recommend Favorite